Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this uncontrolled, multi-center, open-label trial was to investigate the
feasibility of using degarelix as intermittent androgen deprivation (IAD) therapy in the
treatment of prostate cancer.